26 results on '"Molina-Vila, Miguel-Angel"'
Search Results
2. Gene expression signatures in conjunctival fornix aspirates of patients with dry eye disease associated with Meibomian gland dysfunction. A proof-of-concept study
3. Liquid biopsy in detecting early non-small cell lung cancer
4. Overcoming MET-mediated resistance in oncogene-driven NSCLC
5. BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
6. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
7. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
8. Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
9. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
10. Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation
11. Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial
12. Anti–Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells
13. Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC
14. KRAS Mutations in Lung Cancer
15. BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
16. PD.02.02 Lung TS: A New 6-Gene Signature for Prediction of Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Patients
17. PSP.01 Disruptive and Truncating TP53 Mutations Are Frequent in Lung Adenocarcinoma Patients With African Ancestry and Show Worse Prognosis
18. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report
19. Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop
20. P3.02b-047 Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer: Topic: EGFR Clinical
21. P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma: Topic: Functional Biology in Lung Cancer
22. P2.06-010 AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study: Topic: Phase II + NK
23. P2.01-008 SiRe Next Generation Sequencing Panel: Effective Diagnostic Tool for Circulating Free DNA Analysis: Topic: Analysis of Body Fluids in Cancer
24. P1.02-064 MET-Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS-Mutant Lung Cancer: Topic: Other Mutations in Thoracic Malignancies
25. P1.02-020 The Effect of EGF-Pathway Targeted Immunization (EGF PTI) on STAT3 and Cancer Stem Cells in EGFR Mutant NSCLC Cells: Topic: Driver Genes in NSCLC, Resistance, and Other
26. OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.